Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.
Local Biotech Firms Poised to Benefit from Rosy Venture Capital Outlook for 2021
Complementing Your Psychotherapy
CEO of pharmaceutical company praises new, shorter, suicide hotline
CBC Group sets up AffaMed, EverInsight merger, eyes IPO
Benzodiazepines Hit With Boxed Warning by FDA
CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate
Michael Liebowitz, MD, VistaGen CNS Clinical and Regulatory Advisory Board Member and Pivotal Phase 3 Principal Investigator: The Mental Health Impact of COVID-19
The Future of Anxiety Treatment Will Be Drastically Different
Pushing Late-Stage Treatments Forward in the Clinic
